PolyPid rises as lead product granted FDA priority review
The news is that the main product has been designated as a priority review by the FDA. PolyPid's core product has received priority review status from the FDA, attracting market attention.
The stock is experiencing an upward trend, surpassing the resistance level of 4.50, bolstered by the strong catalyst of FDA priority review. Although it exhibited a volatility of -28.5% over the past 7 days and underwent a correction, it is currently trading in a positively aligned moving average state, with trading volume surging to 8.76 times the 20-day average, indicating a strong rebound signal, prompting consideration for entry.
If the upward trend continues after breaking through the resistance level of 4.50, I will sell when it reaches the profit target of $4.8. If the support level of 3.80 is breached, I will sell at the stop-loss price of $3.7.
The RSI(14) is at 32.6, indicating a reversal from a low point, and the moving averages are in a bullish alignment. The trading volume is significantly high, at 8.76 times the 20-day average.
A past similar case is the PYPD case, which had the 'FDA Priority Review' keyword overlap on 2026-08-06. Additionally, the cases of VEEE (2026-07-16) and LRCX (2026-07-06) do not have direct similarities but are noteworthy upper performance cases for reference.
We accurately captured the upward trend accompanied by trading volume, supported by the clear catalyst of FDA priority review. The predicted return was 12.0%, but the actual result was 11.1%, successfully concluding the trade close to the target price of $4.8.
We have once again confirmed the destructive power when the RSI rebounds from a low and trading volume surges. Moving forward, we will prioritize verifying the synchronization of news keywords and trading volume as the basis for entry.